<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03173300</url>
  </required_header>
  <id_info>
    <org_study_id>GLY-000</org_study_id>
    <nct_id>NCT03173300</nct_id>
  </id_info>
  <brief_title>Natural History Study Protocol in PMM2-CDG (CDG-Ia)</brief_title>
  <official_title>Clinical and Basic Investigations Into Phosphomannomutase Deficiency (PMM2-CDG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycomine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glycomine, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG)&#xD;
&#xD;
      This is a natural history (observational) protocol designed to collect clinical and&#xD;
      biological information in patients with PMM2-CDG (CDG-Ia).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects enrolled in this natural history study will be thoroughly examined for signs and&#xD;
      symptoms of PMM2-CDG. Medical history, physical examination, laboratory testing and imaging&#xD;
      studies will be performed during a single consultation. Follow-up will occur every 6 months&#xD;
      at a minimum, depending on the standard of care at the investigator's institution as well as&#xD;
      the clinical status of the individual patient. All medical procedures are routine. No new&#xD;
      therapy is offered as part of this study, and no change in the patients' routine therapy is&#xD;
      dictated by this protocol. No randomization will be performed.&#xD;
&#xD;
      All serious and non-serious adverse events will be recorded in the study CRF database.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>collect clinical and biological information in patients with CDG-PMM2</measure>
    <time_frame>up to 4 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Phosphomannomutase 2 Deficiency</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with PMM2-CDG, all ages&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent/assent by the patient and/or their legally authorized representative&#xD;
&#xD;
          -  Confirmed diagnosis of PMM2-CDG, based on enzymatic or molecular tests&#xD;
&#xD;
          -  Willing and able to adhere to study requirements described in the protocol and&#xD;
             consent/assent documents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected differential diagnosis of any other known CDG (not PMM2-CDG)&#xD;
&#xD;
          -  Currently using investigational drug&#xD;
&#xD;
          -  Blood loss of &gt;250 mL or donated blood within 56 days, or donated plasma within 7&#xD;
             days, of study screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horacio Plotkin, MD / Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Glycomine, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tulane University Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic College of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia (CHOP)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital in Prague</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Necker Enfants-Malades Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Catania</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Nejmegen Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mother and Child Institute (Instytut Matki i Dziecka)</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de DÃ©u</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PMM2-CDG</keyword>
  <keyword>CDG-Ia</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

